KZIA Kazia Therapeutics Ltd ADR

USD 0.37 -0.02 -4.884319
Icon

Kazia Therapeutics Ltd ADR (KZIA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.37

-0.02 (-4.88)%

USD 7.11M

0.17M

N/A

N/A

Icon

KZIA

Kazia Therapeutics Ltd ADR (USD)
COMMON STOCK | NSD
USD 0.37
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 7.11M

N/A

USD 0.37

Kazia Therapeutics Ltd ADR (KZIA) Stock Forecast

N/A

Based on the Kazia Therapeutics Ltd ADR stock forecast from 0 analysts, the average analyst target price for Kazia Therapeutics Ltd ADR is not available over the next 12 months. Kazia Therapeutics Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Kazia Therapeutics Ltd ADR is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Kazia Therapeutics Ltd ADR’s stock price was USD 0.37. Kazia Therapeutics Ltd ADR’s stock price has changed by +6.87% over the past week, +38.06% over the past month and -72.09% over the last year.

No recent analyst target price found for Kazia Therapeutics Ltd ADR
No recent average analyst rating found for Kazia Therapeutics Ltd ADR

Company Overview Kazia Therapeutics Ltd ADR

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse i...Read More

Three International Towers, Sydney, NSW, Australia, 2000

0

June

USD

USA

Adjusted Closing Price for Kazia Therapeutics Ltd ADR (KZIA)

Loading...

Unadjusted Closing Price for Kazia Therapeutics Ltd ADR (KZIA)

Loading...

Share Trading Volume for Kazia Therapeutics Ltd ADR Shares

Loading...

Compare Performance of Kazia Therapeutics Ltd ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for KZIA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Kazia Therapeutics Ltd ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.06 (-0.76%) USD107.38B 29.93 21.06

ETFs Containing KZIA

Symbol Name KZIA's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Kazia Therapeutics Ltd ADR (KZIA) Stock

Stock Target Advisor's fundamental analysis for Kazia Therapeutics Ltd ADR's stock is Bearish.

Unfortunately we do not have enough data on KZIA's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on KZIA's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on KZIA's stock to indicate if its overvalued.

The last closing price of KZIA's stock was USD 0.37.

The most recent market capitalization for KZIA is USD 7.11M.

Unfortunately we do not have enough analyst data on KZIA's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Kazia Therapeutics Ltd ADR's stock.

As per our most recent records Kazia Therapeutics Ltd ADR has 0 Employees.

Kazia Therapeutics Ltd ADR's registered address is Three International Towers, Sydney, NSW, Australia, 2000. You can get more information about it from Kazia Therapeutics Ltd ADR's website at https://www.kaziatherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...